GlassScriptPhysician profile
Sheri Denham
NPI 1295279214
$7,136.77
in general payments reported to CMS, 2019-2025
17 companies · $3,765 in 2025
The $3,765 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $827 · 2022: $1,064 · 2023: $792 · 2024: $689 · 2025: $3,765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,509 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,403 · Travel and Lodging: $334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,509.04 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,403.00 |
| Travel and Lodging | $334.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $3,390.75 | 2021-2025 | Sublocade, Opvee |
| Abbvie INC. | $915.39 | 2021-2025 | |
| Uswm, LLC | $523.35 | 2021-2023 | Zimhi, Lucemyra |
| Alkermes, INC. | $505.49 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Novo Nordisk INC | $356.21 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Braeburn INC. | $342.37 | 2023-2025 | Brixadi |
| Lilly USA, LLC | $332.06 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $175.48 | 2023-2025 | Caplyta |
| Orexo US, INC. | $151.22 | 2021-2023 | Zubsolv |
| Lundbeck LLC | $146.88 | 2021-2025 | Rexulti |
| Revance Therapeutics, INC. | $105.21 | 2024 | Daxxify |
| Vanda Pharmaceuticals INC. | $80.36 | 2024-2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $31.37 | 2022 | |
| Supernus Pharmaceuticals, INC. | $25.69 | 2025 | Qelbree |
| Janssen Pharmaceuticals, INC | $21.52 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $18.90 | 2025 | |
| Currax Pharmaceuticals LLC | $14.52 | 2025 | Contrave, Onzetra Xsail |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheri Denham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.